斯通里奇 SRI 深 沪
已收盘 02-06 16:00:00 美东时间
8.47
+0.430
+5.35%
华盛通- 最 高8.56
- 今 开8.06
- 成交量 28.19万股
- 最 低 8.06
- 昨 收 8.04
- 总市值 2.37亿
- 52周最高 9.10
- 市盈率 静 --
- 换手率 1.01%
- 52周最低 3.54
- 委 比 7.53%
- 总股本 2801.69万
- 历史最高 38.20
- 量 比 0.96
- 振 幅 6.22%
- 历史最低 3.54
- 每 手 1
- 风险率 1.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Stoneridge Announces Chief Financial Officer Departure
NOVI, Mich., Feb. 2, 2026 /PRNewswire/ -- Stoneridge, Inc. (NYSE: SRI) today announced that Chief Financial Officer and Treasurer, Matt Horvath, has resigned, effective March 31, 2026, to pu...
02-03 06:20
Stoneridge Completes Sale Of Control Devices Segment To Affiliate Of Center Rock Capital Partners; Deal Closed On January 30 With Base Purchase Price Of $59M
Stoneridge, Inc. (NYSE:SRI) today announced that it has completed the sale of its Control Devices segment to an affiliate of Center Rock Capital Partners, LP ("Center Rock"), a private investment firm specializing in
02-02 20:33
Stoneridge Completes Strategic Review with Sale of Control Devices Segment
Transaction Closed January 30, 2026, with a Base Purchase Price of $59 Million NOVI, Mich., Feb. 2, 2026 /PRNewswire/ -- Stoneridge, Inc. (NYSE: SRI) today announced that it has completed th...
02-02 20:30
Stoneridge Amends Credit Agreement for Financial Relief
Stoneridge ( ($SRI) ) has provided an update. On November 5, 2025, Stoneridge a...
2025-11-06 06:59
Stoneridge Narrows FY2025 Sales Guidance from $860.000M-$890.000M to $860.000M-$870.000M
Stoneridge (NYSE:SRI) narrows FY2025 sales outlook from $860.000 million-$890.000 million to $860.000 million-$870.000 million.
2025-11-06 06:06
Stoneridge Q3 Adj. EPS $(0.18), Sales $210.267M Beat $203.139M Estimate
Stoneridge (NYSE:SRI) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.07) by 157.14 percent. This is a 25 percent increase over losses of $(0.24) per share from the same
2025-11-06 06:06
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
2025-11-04 10:31
Barrington Research Maintains Outperform on Stoneridge, Maintains $16 Price Target
Barrington Research analyst Gary Prestopino maintains Stoneridge (NYSE:SRI) with a Outperform and maintains $16 price target.
2025-11-03 21:12
Sipa Resources Issues 8 Million Unquoted Securities
Sipa Resources Limited ( ($AU:SRI) ) has shared an update. Sipa Resources Limit...
2025-09-09 16:27
Sipa Resources Director Increases Stake in Strategic Move
Sipa Resources Limited ( ($AU:SRI) ) just unveiled an announcement. Sipa Resour...
2025-09-09 16:27
